It’s been exactly 3 years since Starpharma announced a development and option agreement with AstraZeneca.
Starpharma would do all the legwork, apply all the resources and spend all the $$$ in pre-clinical work to get to a point where either; •AZ would have the option to licence the DEP version for a whopping US$5 million for further development by them, or •alternatively Starpharma would have the option to licence the DEP drug from AZ to develop further
It’s been 3 years and we’ve heard sweet FA about this. Are they still working on it? Has it been shelved? Is it still on foot but been de-prioritised? Of course shareholders have to guess because part-time CEO Jackie Fairley and Starpharma have a long and extensive history of announcing major price-sensitive developments, only for nothing to occur and drift off into magic fairy bullshit dust land many years later without any accountability.
